Lung Cancer - Multimodality Therapy

Podcast

The Beat With Joel Dunning Ep. 174: Surgical Treatment of Atrial Fibrillation

September 17, 2026 | Joel DunningGold ContributorSilver Commentor…

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with James Cox, Professor of Cardiac Surgery at the Feinberg School of Medicine at Northwestern Medicine in Chicago, Illinois, USA, and Patrick McCarthy, Executive Director...

Video

Robotic Approach as the Gold Standard for Immunotherapy Lung Resections

October 19, 2026 | Alessandra Bennati…

The neoadjuvant chemoimmunotherapy pathway has become the standard of care for patients with resectable, locally advanced non-small cell lung cancer without actionable mutations. Its increasing use has introduced novel technical...

Podcast

The Beat With Joel Dunning Ep. 174: Surgical Treatment of Atrial Fibrillation

September 17, 2026 | Joel DunningGold ContributorSilver Commentor…

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with James Cox, Professor of Cardiac Surgery at the Feinberg School of Medicine at Northwestern Medicine in Chicago, Illinois, USA,...

JANS Article

Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid

September 10, 2026 | Akshay PatelSilver Contributor

In this Memorial Sloan Kettering series, 11 patients with metastatic DLL3-high pulmonary carcinoid received the DLL3/CD3 bispecific T-cell engager tarlatamab. Eight patients (73 percent) achieved an objective response; all had...

JANS Article

Surgical Outcomes After Chemotherapy Plus Nivolumab and Chemotherapy Plus Nivolumab and Ipilimumab in Patients With Non-Small Cell Lung Cancer

April 18, 2024 | Mujtaba MubashirGold Contributor

This study reviews 44 patients with stage IB (larger than 4 cm) to IIIA non-small cell lung cancer who were treated on sequential platform arms of the NEOSTAR trial. Twenty-two...

Video

Making Difficult Decisions in Lung Cancer: Oligometastasis, Ground Glass Opacities, Bilateral Lung Lesions, Surgery for Recurrence

July 5, 2018 | Gilbert Massard

Gilbert Massard of the Centre Hospitalier in Strasbourg, France, discusses difficult treatment decisions in lung cancer. He reviews the different treatment approaches for oligometastasis, ground glass opacities, and multiple primary...

JANS Article

Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base

April 13, 2018 | Mark FergusonGold Contributor

The authors found that adjuvent chemoradiotherapy after resection of N2 NSCLC was more effective if given sequentially than concomitantly.

...
JANS Article

Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

February 5, 2018 | Mark FergusonGold Contributor

This randomized trial compared chemoradiotherapy alone to chemoradiotherapy followed by consolidation therapy with the PDL-1 antibody durvalumab in patients with stage III NSCLC. The treatment group had significantly improved progression-free...

JANS Article

Lung Cancer Awareness Month—A Lot of Progress, But More Work Needs to Be Done

October 24, 2017 | Mark FergusonGold Contributor

A useful reminder of the substantial progress that has been made and the continuing challenges that we face in fighting this terrible disease.

...
JANS Article

Scientific Advances in Thoracic Oncology 2016

August 2, 2017 | Mark FergusonGold Contributor

This is an excellent summary of progress during the past year in all aspects of lung cancer, from prevention/detection through molecular therapies and future perspectives. Each section is written by...

JANS Article

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer

August 28, 2016 | Mark FergusonGold Contributor

The authors tested the hypothesis that induction therapy improves survival in patients undergoing resection for clinical N1 disease using information from the National Cancer Data Base. 10% of over 5,000...

JANS Article

Adjuvant Chemotherapy for T3 Non-Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe

July 15, 2016 | Lisa BrownBronze Contributor

This is a retrospective National Cancer Data Base cohort study of patients with pathologic stage T3 invasive NSCLC with separate tumor nodules in the same lobe. The goal was to...

JANS Article

Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter?

November 16, 2015 | Mark FergusonGold Contributor

The relationship to institution type and survival after multimodality therapy for IIIA NSCLC was investigated using the NCDB (National Cancer Database). Academic medical centers had a higher incidence of induction...

LOAD MORE
ADVERTISE ON CTSNET